Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 17;16:2. doi: 10.1186/s13045-023-01399-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — BC31M4 causes minimal hematotoxicity in C57-hCD47/hSIRPα mice. a Top, schematic diagram of mouse treatment and body temperature measurement. ‘0’ indicates no priming dosing. Bottom, body temperature changes compared to the average temperature in the corresponding control group; each histogram represents one mouse. b Summary of the treatment-related-death of the antibody treated mice. c Hemagglutination test of antibodies in vitro. RBC aggregation was analyzed by flow cytometry. Dot plots of the FSC-A and SSC-A values are shown; percentage of events in the gate (red frame) is denoted. d, e, g–i Summary of the complete blood count test of antibody-treated mice. The parameters of RBC count (d), red cell distribution width (e), platelet count (g), mean platelet volume (h), and the proportion of individual leukocytes in WBCs (i) are shown. f Spleen weight of mice used in the complete blood count test. Antibodies used in (a–f) are mIgG2a isotype unless otherwise noted